Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 31.01.2006 Intercell (VSE; "ICLL") today announced initial data from a clinical trial aiming at the optimization of its therapeutic Hepatitis C vaccine IC41. Results indicate that IC41, given in ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 30.01.2006 Intercell AG (VSE, "ICLL") announced today that the companys Japanese Encephalitis vaccine, currently in advanced Phase III trials, has been granted orphan drug status by the ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 12.01.2006 Intercell AG (VSE, "ICLL") announced today the achievement of an important milestone in the progress of its international, multi-center Phase III clinical trial program of its Japanese Encephalitis vaccine: An independent Data and ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 09.01.2006 Vienna (Austria), January 9, 2006 - Intercell AG (VSE, "ICLL") announced today that the next milestone within the collaboration with sanofi pasteur for the development of a bacterial ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 29.12.2005 Intercell AG (VSE, "ICLL") today announced that the following persons have resigned as members of the supervisory board of the company: Emilio A. Emini, who joined Intercells Supervisory Board in January 2005, has taken on new ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 15.12.2005 Vienna (Austria), December 15, 2005 - Intercell AG (VSE, "ICLL") today announced the start of a Phase I clinical trial by Merck&Co., Inc., for a vaccine against Staphylococcus aureus ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 09.12.2005 Vienna (Austria), December 9, 2005 - Intercell AG today announced the signing of an exclusive license agreement with Pelias Biomedical Development AG (Pelias) in the field of ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 18.11.2005 A new tuberculosis (TB) vaccine has been designed at Statens Serum Institut (SSI), Copenhagen. While the current TB vaccine, the Calmette (BCG) vaccine, efficiently protects children against TB, protection gradually decreases after 10-15 ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 14.11.2005 Conference Call regarding the report Q3 2005 Monday, November 14, 2005 - 14.30 CET Tel: +43-1-23032 - PIN: 501114 The full quarterly report including un-audited financial statements ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 10.11.2005 Intercell AG today announced that the European Patent Office has granted a European Patent 1355930 entitled "A method for identification, isolation and production of antigens to a ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 02.11.2005 Intercell AG (VSE, "ICLL") announced today that it has received a milestone payment of USD 1 million from Merck & Co., Inc. for significant progress made in the development of a ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 24.10.2005 Intercell AG (VSE, "ICLL") today announced that the company's Supervisory Board has appointed its management board with new responsibilities for the next three years. This ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 20.10.2005 Vienna, Austria, October 20, 2005 - Vaccine Company Intercell AG (VSE, "ICLL") reports significant pre-clinical progress for its protein-based Pneumococcus vaccine as one of its next ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 19.09.2005 Vienna, Austria, September 19, 2005 - Intercell AG (VSE, "ICLL") announced today the start of global multi-center Phase III clinical trials of its Japanese Encephalitis vaccine, IC51. ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 30.08.2005 Vienna, Austria, August 30, 2005 - Intercell AG announced today the signature of an exclusive agreement with CSL Ltd. for the Marketing and Distribution of Intercell´s novel cell ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 12.08.2005 »EMEA Scientific Advice confirms Intercells development strategy for Japanese Encephalitis Vaccine to be suitable for licensure in Europe »Preparation of JEV Phase III clinical ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 09.08.2005 Vienna - August 9, 2005 - Intercell AG (VSE - "ICLL") today announced that the company has received the approval for the start of Phase III clinical studies for the Japanese ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 01.07.2005 Vienna - July 1, 2005 - Intercell AG (VSE - "ICLL") today announced that its partner sanofi pasteur S.A. (previously aventis pasteur S.A.), the vaccines business of the sanofi-aventis ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 27.06.2005 Vienna / Copenhagen / Bethesda, June 27, 2005 - Intercell AG and Statens Serum Institut (SSI) announced today that their joint project for the development of a new prophylactic ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 14.06.2005 Vienna - June 14, 2005 - Intercell AG announced today the receipt of an R&D grant from the National Institute of Health (NIH) of the United States amounting to $ 6.6m. The grant ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 23.05.2005 Vienna, Austria, May, 23, 2005 - Intercell, a leading developer of next generation vaccines for the prevention and treatment of major infectious diseases reported the start of its ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 09.05.2005 Conference Call regarding the report Q1 2005 Monday, May 9, 2005 14.30 CET Tel: +43.1.23032 PIN: 122448 - Strong financial position with more than EUR 70 million in cash reserves ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 03.05.2005 Vienna (Austria), May 3, 2005 - Intercell AG (Vienna Stock Exchange: ICLL), today announced completion of recruitment in a new clinical trial of its therapeutic vaccine IC41 against ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 18.03.2005 Goldman Sachs International today exercised the over-allotment option granted in connection with Intercell AGs initial public offering. The over-allotment shares comprise 277,935 shares provided by existing shareholders and 989,132 ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 17.03.2005 Vienna (Austria), March 17, 2005 - Intercell AG, a leading developer of next generation vaccines for the prevention and treatment of major infectious diseases, announced today that ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 28.02.2005 Vienna, 28 Februar 2005 - Shares of Intercell AG began trading today on the Prime Market segment of the official market (Amtlicher Handel) of the Vienna Stock Exchange (Wiener ...
Disclosure announcement transmitted by euro adhoc. The issuer is responsible for the content of this announcement. 25.02.2005 Vienna, February 25, 2005 - The Austria-based vaccine company Intercell AG has priced its initial public offering (IPO). The offer consisted of an initial public offering in Austria ...